EN
SINOVAC Made Major Announcements Today
On June 4, 2024, Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin met with Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, in Beijing, China.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin (Right) meet with
SINOVAC Chairman, President, and CEO Weidong Yin (Left)
SINOVAC, whose COVID-19 vaccines are the first to enter the Brazilian market during the pandemic, is a leading biopharmaceutical enterprise in China. Today, the company made major announcements of investment in Brazil as follows:
Firstly, SINOVAC plans to invest $100 million in Brazil starting in 2024, mainly for cell therapy and localized production of vaccines and monoclonal antibodies. Currently, SINOVAC is engaged in intensive discussions with potential partners.
Secondly, SINOVAC and Fiocruz jointly announced their intention to cooperate in vaccine research and development. In this way, both sides jointly strengthen their roles as the official representatives of Brazil and China, respectively, in the BRICS vaccine R&D center, established in 2022. This center aims to enhance the production capacity of participating countries and make access to vaccines more equitable. The institutions already signed the confidentiality document, which is the first step in establishing a partnership to search for solutions that expand access to vaccines and quickly combat pandemics and health crises. During the WHA77 in Geneva, BRICS health ministries reaffirmed their commitment to this important initiative for global health.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin meet with
Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com